Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

Eli Lilly's operational performance is strong ... other drugs in its portfolio such as Trulicity are being viewed as relics of a bygone era. Year over year, Trulicity sales dropped from $1. ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... particularly from players like Novo Nordisk. Due to this, Trulicity's performance saw a 22% revenue decline in Q3 2024 to $1.3 billion driven ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...